Docoh
Loading...

73 results

Filter options loading...
Top filers
Top filing types
Recent filing years
424B5
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Prospectus supplement for primary offering
4:46pm
and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
and biological materials or relating to the protection or restoration of the environment or human exposure to hazardous chemicals, toxic substances
S-3
PCSA Processa Pharmaceuticals Inc
30 Jun 21
Shelf registration
4:02pm
, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time to time
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
regulatory environment, any issues regarding the ability to Manufacture the Compound or Product, the likelihood and timing of obtaining Regulatory … , competitive Third-Party products at the time and the likely competitive environment at the time of projected entry into the market and thereafter, and any other
424B3
PCSA Processa Pharmaceuticals Inc
12 Apr 21
Prospectus supplement
1:44pm
environment, and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all
S-3
PCSA Processa Pharmaceuticals Inc
1 Apr 21
Shelf registration
8:00pm
of risks, uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment, and new risks emerge from time
10-K
2020 FY
PCSA Processa Pharmaceuticals Inc
24 Mar 21
Annual report
8:00pm
in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for our management to predict all risks … and competitive environment in which we operate. Biopharmaceutical product development is a highly speculative undertaking, involves a substantial degree
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
18 Feb 21
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing
10:08am
or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws … (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing, distribution, use, treatment, storage
8-K
EX-1.1
PCSA Processa Pharmaceuticals Inc
6 Oct 20
Processa Pharmaceuticals Announces Pricing of $19.2 Million Public Offering and Uplisting to the Nasdaq Capital Market
4:05pm
financial reporting related to our control environment, which in turn results in a material weakness in our disclosure controls. If we do not remediate … , relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human
424B4
PCSA Processa Pharmaceuticals Inc
5 Oct 20
Prospectus supplement with pricing info
4:16pm
and commercialization efforts; We have identified material weaknesses in our internal control over financial reporting related to our control environment, which … with developing and expanding early-stage businesses and the regulatory and competitive environment in which we operate. Biopharmaceutical product development
S-1/A
PCSA Processa Pharmaceuticals Inc
30 Sep 20
IPO registration (amended)
4:06pm
weaknesses in our internal control over financial reporting related to our control environment, which in turn results in a material weakness in our … businesses and the regulatory and competitive environment in which we operate. Biopharmaceutical product development is a highly speculative undertaking
S-1/A
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
efforts; We have identified material weaknesses in our internal control over financial reporting related to our control environment, which in turn … and competitive environment in which we operate. Biopharmaceutical product development is a highly speculative undertaking, involves a substantial degree of risk
S-1/A
EX-2.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
of any applicable statute, Law or Regulation relating to the environment or occupational health and safety, which violation would have a Company … statute, Law or Regulation relating to the environment or occupational health and safety, which violation would have a HUWX Material Adverse Effect
S-1/A
EX-1.1
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
control environment, which in turn results in a material weakness in our disclosure controls. If we do not remediate the material weaknesses in our internal … or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic
S-1/A
EX-10.13
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
, present and future regulatory environment, any issues regarding the ability to Manufacture the Compound or Product, the likelihood and timing … exclusivity, competitive Third Party products at the time and the likely competitive environment at the time of projected entry into the market
S-1/A
EX-10.11
PCSA Processa Pharmaceuticals Inc
16 Sep 20
IPO registration (amended)
8:00pm
or projected pricing, sales, reimbursement and financial return, medical and clinical considerations, present and future regulatory environment, any … at the time and the likely competitive environment at the time of projected entry into the market and thereafter, and any other relevant scientific
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
27 Aug 20
Entry into a Material Definitive Agreement
9:30am
, present and future regulatory environment, any issues regarding the ability to Manufacture the Compound or Product, the likelihood and timing … exclusivity, competitive Third Party products at the time and the likely competitive environment at the time of projected entry into the market
8-K
EX-10.1
PCSA Processa Pharmaceuticals Inc
20 Aug 20
Entry into a Material Definitive Agreement
9:30am
or projected pricing, sales, reimbursement and financial return, medical and clinical considerations, present and future regulatory environment, any … at the time and the likely competitive environment at the time of projected entry into the market and thereafter, and any other relevant scientific
10-Q
2020 Q2
PCSA Processa Pharmaceuticals Inc
5 Aug 20
Quarterly report
3:32pm
and property rights, competition, rapid technological change, navigating the domestic and major foreign markets’ regulatory and clinical environment … foreign markets’ regulatory and clinical environment, recruiting and retaining key personnel, dependence on third party manufacturing organizations
S-1/A
PCSA Processa Pharmaceuticals Inc
17 Jul 20
IPO registration (amended)
5:25pm
encountered in connection with developing and expanding early-stage businesses and the regulatory and competitive environment in which we operate … , the continuing development of new drug technology, and the competitive and regulatory environment in which we operate or may choose to operate